According to GuruFocus Insider Data, these are the largest CEO buys during the past week.
OPKO Health CEO bought 294,527 shares
OPKO Health Inc. (OPK, Financial) CEO, Chairman and 10% Owner Phillip Frost bought 294,527 shares during the week at an average price of $3.06.
The diversified health care company, whose business includes diagnostics and provision of pharmaceutical products, has a market cap of $1.67 billion. Its shares traded around $2.99 on Friday.
Consolidated revenue for the quarter ended Dec. 31 was $193.7 million, compared to $275.5 million in the prior-year period.
Frost bought 60,000 shares on April 6 at a price of $3.10; 80,000 shares on April 9 at a price of $3.04; 36,527 shares on April 10 at a price of $3.06; 43,000 shares on April 11 at a price of $3.06; and 65,000 shares on April 12 at a price of $3.04. The price of the stock has decreased by 1.64% since.
Director Robert Scott Fishel bought 10,000 shares on April 6 at a price of $3.16. The price of the stock has decreased by 5.38% since.
Intercept Pharmaceuticals CEO bought 7,812 shares
Intercept Pharmaceuticals Inc. (ICPT, Financial) CEO and President Mark Pruzanski bought 7,812 shares on April 9 at a price of $64.00. The price of the stock has increased by 14.17% since.
Intercept Pharmaceuticals is a biopharmaceutical company. It is focused on the development and commercialization of novel therapeutics to treat non-viral, progressive liver diseases with high unmet medical need. The company has a market cap of $1.84 billion. Its shares traded at $73.07 on Friday.
Net loss for the three months ended Dec. 31, 2017, was $111.3 million compared to a net loss of $120.0 million for the prior-year period.
On April 5 the company announced that it priced its public offering of 2,343,750 shares of its common stock at a price to the public of $64.00 per share.
10% Owner Genextra S.p.A bought 390,625 shares on April 9 at a price of $64. The price of the stock has increased by 14.17% since.
10% Owner Francesco Micheli bought 390,625 shares on April 9 at a price of $64. The price of the stock has increased by 14.17% since.
Director Keith Michael Gottesdiener bought 1,171 shares on April 9 at a price of $64. The price of the stock has increased by 14.17% since.
Director Daniel Bradbury bought 7,812 shares on April 9 at a price of $64. The price of the stock has increased by 14.17% since.
New Media Investment Group CEO bought 25,000 shares
New Media Investment Group Inc. (NEWM, Financial) CEO Michael Reed bought 25,000 shares on April 10 at a price of $16.45. The price of the stock has increased by 3.95% since.
New Media Investment Group owns, operates and invests in local media assets. The company focuses on two categories, consumers and small to medium-sized businesses. The company has a market cap of $904.33 million. Its shares traded at $17.10 on Friday.
Net income for the fourth quarter was $26.4 million compared to net loss of $2.0 million for the prior-year period.
On April 5 the company announced the launch of its public offering of 6 million shares of its common stock.
Macy's CEO bought 10,000 shares
Macy's Inc. (M, Financial) Chairman and CEO Jeffrey Gennette bought 10,000 shares on April 12 at a price of $29.10. The price of the stock has decreased by 2.89% since.
Macy's is an omnichannel retailer. It sells merchandise, including men's, women's and children's apparel and accessories, cosmetics, home furnishings and other consumer goods. The company has a market cap of $8.61 billion. Its shares traded at $28.26 with a price-earnings (P/E) ratio of 5.61 on Friday.
Net income for the fourth quarter of 2017 was $1.33 billion compared to $475 million for the comparable period of 2016.
Director Gary Lambert Bentham bought 370 shares on April 6 at a price of $6.
Director Roger H. Giovanetto sold 143 shares on April 5 at a price of $5.86.
Executive Vice President, Controller and Enterprise Risk Felicia Williams sold 785 shares on Mar. 28 at a price of $28.99. The price of the stock has decreased by 2.52% since.
Aclaris Therapeutics CEO bought 10,000 shares
Aclaris Therapeutics Inc. (ACRS, Financial) President and CEO Neal Walker bought 10,000 shares on April 5 at a price of $16.75. The price of the stock has increased by 5.19% since.
Aclaris Therapeutics is a clinical-stage specialty pharmaceutical company that focuses on identifying, developing and commercializing differentiated drugs to address significant unmet needs in dermatology. The company has a market cap of $544.48 million. Its shares traded at $17.62 with a price-earnings (P/E) ratio of on Friday.
Net loss for the fourth quarter of 2017 was $22.9 million compared to $11.5 million for the fourth quarter of 2016.
CFO Frank Ruffo bought 1,250 shares on April 6 at a price of $16.59. The price of the stock has increased by 6.21% since.
Director Stephen A. Tullman bought 26,700 shares on April 6 at a price of $16.54. The price of the stock has increased by 6.53% since.
Director Christopher P. Molineaux sold 2,300 shares on April 6 at a price of $16.52. The price of the stock has increased by 6.66% since.
For the complete list of stocks that were bought by their company CEOs, go to: CEO Buys.
Disclosure: I do not own stock in any of the companies mentioned in the article.
